Missed opportunities for the secondary prevention of cardiovascular disease in CanadaPrévention secondaire des maladies cardiovasculaires au Canada : Occasions manquées pour la
References (53)
- et al.
Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis
Lancet
(2003) - et al.
From knowledge to practice in chronic cardiovascular disease: A long and winding road
J Am Coll Cardiol
(2004) - et al.
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group
Lancet
(2000) - et al.
Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction
Am J Med
(2003) - et al.
Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: A cohort study
Lancet
(2005) - et al.
Cardiovascular risk factors in type 2 diabetic patients: Multifactorial intervention in primary care
Kidney Int Suppl
(2005) Practical considerations of beta-blockade in the management of the post-myocardial infarction patient
Am Heart J
(2005)- et al.
Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia
Am J Cardiol
(2001) - et al.
Canadian Association of Cardiac Rehabilitation. Canadian guidelines for cardiac rehabilitation and atherosclerotic heart disease prevention: A summary
Can J Cardiol
(2001) Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
BMJ
(2002)
Oral anticoagulants in patients with coronary artery disease
J Am Coll Cardiol
Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials
Lancet
Effects of long-term treatment with angiotensin-convertingenzyme inhibitors in the presence or absence of aspirin: A systematic review
Lancet
Task Force on Beta-blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers
Eur Heart J
Efficacy and safety of cholesterollowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
Lancet
Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis
Circulation
AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
Circulation
Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias
CMAJ
The 2001 Canadian recommendations for the management of hypertension: Part one – assessment for diagnosis, cardiovascular risk, causes and lifestyle modification
Can J Cardiol
The 2001 Canadian recommendations for the management of hypertension: Part two – therapy
Can J Cardiol
Elevated levels of serum creatinine: Recommendations for management and referral
CMAJ
Canadian Cardiovascular Society. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure
Can J Cardiol
Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada
Can J Diabetes
The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: Heart failure as an example
Am J Manag Care
Are data from clinical registries of any value?
Eur Heart J
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
N Engl J Med
Cited by (26)
Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF)
2017, American Journal of CardiologyCitation Excerpt :While morbidity and mortality in AF patients is high, antithrombotic therapy aimed at stroke and systemic embolism prevention may only modestly contribute to overall CV event reduction.6,7 While previous studies have demonstrated underutilization of EBT in outpatients with CV co-morbidities and risk factors,16–22 a unique feature of the present analysis relates to our assessment of such treatments in the context of AF. Indeed, the FREEDOM AF and CONNECT AF populations had a high co-morbidity profile.
Management of risk factors among ambulatory patients at high cardiovascular risk in canada: A follow-up study
2013, Canadian Journal of CardiologyCitation Excerpt :VP and GOALL registries enrolled patients at high risk for or with established atherosclerotic disease, including coronary artery disease (CAD), cerebrovascular disease, or peripheral artery disease (PAD). Details have been published previously.9-11 To enhance the generalizability of the registry findings, there were no specific exclusion criteria, and participating physicians were instructed to enroll consecutive eligible patients.
Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care
2011, Contemporary Clinical TrialsCitation Excerpt :A nationally representative survey in Australian primary care found that only 50% of those with previous CVD were prescribed all three categories of preventive medications [11]. Similar low rates have been found in Europe and North America [12–14]. Amongst patients without previous CVD but at high risk, prescription rates are even lower [11,13,15].
Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk guideline-based undertaking to improve dyslipidemia management in Canada (GUIDANC)
2011, Canadian Journal of Cardiology